Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


Arpitha Parthasarathy

Arpitha Parthasarathy

US Medical Innovations, USA

Title: Advances in Retinoblastoma


Biography: Arpitha Parthasarathy


Retinoblastoma (RB1) is a progressive cancer which mainly occurs in children, which is caused by genetic or epigenetic\r\nalterations that lead to inactivation of both alleles of the RB1 gene. Retinoblastoma accounts for 11% of cancer in the\r\nfirst year of life. Recent studies have suggested the use of intravitreal therapy using VEGF as a photodynamic therapy,\r\nhowever, chemoprophylaxis for tumor treatment regimen still seems to be the best accepted approach for tumor bearing\r\nretinoblastoma. Recent studies have suggested that mRNA-365 targets cyclin dependent kinase 6/4 induces tumor progression\r\nand yet chemotherapeutic intervention has been the only available method as therapy. We report for the first time in the field\r\nof ocular tumors, that the cold atmospheric plasma induces an altered energy metabolism via redox potential and induces\r\nspecific receptors like TRAIL-R1 to be elevated causing cell death of retinoblastoma cells in vitro. The elevated expression\r\nof TNF-associated receptor TRAIL-R1 induces DNA nick and apoptosis possibly via p53 and Nf-kb pathway. The specificity\r\nand selectivity of tumor cell death/apoptosis with the use of cold atmospheric plasma suggests that a combination of cold atmospheric plasma along with reduced doses of chemotherapeutic drug will highlight the significance in the treatments of ocular tumors.